Oppenheimer Acted as Co-Lead Manager for ArQule, Inc.
ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. ArQule’s mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients. Our clinical-stage pipeline consists of four drug candidates, all of which are in targeted, biomarker-defined patient populations, making ArQule a leader among companies our size in precision medicine.
ArQule’s pipeline includes: ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of both wild type and C481S-mutant BTK, in phase 1 for patients with B-cell malignancies refractory to other therapeutic options; miransertib (ARQ 092), a potent and selective inhibitor of the AKT serine/threonine kinase, in a planned registrational trial with cohorts in Proteus syndrome and PROS to initiate in 2019; ARQ 751, a next generation highly potent and selective AKT inhibitor, in phase 1 for patients with AKT1 and PI3K mutations; and derazantinib, a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family, in a registrational trial for iCCA in collaboration with Basilea and Sinovant. ArQule’s current discovery efforts are focused on the identification and development of novel kinase inhibitors, leveraging the Company’s proprietary library of compounds.
For more information please contact:
Healthcare Investment Banking Equity Capital Markets
Michael A. Margolis, R.Ph. Peter Bennett
Co-Head of Healthcare Investment Banking Head of Equity Capital Markets
212-667-7622 212-667-6285
MichaelA.Margolis@opco.com Peter.Bennett@opco.com
This notice is provided for informational purposes only, and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.
This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.
Oppenheimer and Oppenheimer Asset Management Inc (OAM) are principle subsidiaries of Oppenheimer Holdings Inc., and provide a full range of wealth management, securities brokerage, capital markets, and investment banking services to high-net worth individuals, families, corporate executives, businesses and institutions. The Firm creates integrated financial strategies tailored to each client’s goals. For over 130 years of operation, Oppenheimer has emphasized customer service, integrity and intellectual objectivity.
2019 Oppenheimer & Co. Inc. Transacts Business on all Principal Exchanges and Member SIPC 2636648.1